Rapport 2009 sur l'état des connaissances relatives aux biomarqueurs tissulaires uPA/PAI-1, Oncotype DX™ et MammaPrint® dans la prise en charge du cancer du sein

Élisabeth Luporsi; Fabrice André; Jean Pierre Bellocq; Yves Caron; Reims Pierre Fumoleau; Anne Gompel; Pierre Marie Martin; Henri Roché; Rémy Salmon; Brigitte Sigal-Zafrani; Frédérique Spyratos

doi:10.1007/s10269-009-1851-5

Rapport 2009 sur l'état des connaissances relatives aux biomarqueurs tissulaires uPA/PAI-1, Oncotype DX™ et MammaPrint® dans la prise en charge du cancer du sein

Élisabeth Luporsi, Fabrice André, Jean Pierre Bellocq, Yves Caron, Reims Pierre Fumoleau, Anne Gompel, Pierre Marie Martin, Henri Roché, Rémy Salmon, Brigitte Sigal-Zafrani, Frédérique Spyratos

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

2 Citations (Scopus)

Résumé

This report evaluates the prognostic and the predictive values of the following tumor markers in breast cancer management: uPA/PAI-1, Oncotype DX™, and MammaPrint®. The report is based on literature appraisal and judgment of a panel of experts. For the prognostic value, only uPA/PAI-1 reached the highest level of evidence, LOE I. Because meta-analysis and dedicated randomized clinical trials were lacking, Oncotype DX™ and MammaPrint® reached lower levels of evidence, LOE II and LOE III, respectively. For the predictive value, only uPA/PAI-1 and Oncotype DX™ reached the intermediate level of evidence, LOE II. This review also describes the analytical methods, identifies the main ongoing clinical trials, and proposes perspectives for further research. This work was elaborated by the French National Cancer Institute (INCa) and the Sociétéfrançaise de sénologie et de pathologie mammaire.

Titre traduit de la contribution	2009 Report on the state of knowledge concerning tissue biomarkers uPA-PAI-1, Oncotype DX™ and Mammaprint® in breast cancer management
langue originale	Français
Pages (de - à)	158-163
Nombre de pages	6
journal	Oncologie
Volume	12
Numéro de publication	2
Les DOIs	https://doi.org/10.1007/s10269-009-1851-5
état	Publié - 1 févr. 2010

mots-clés

Breast cancer
MammaPrint®
Oncotype DX™
Predictive value
Prognostic value
uPA/PAI-1

Accès au document

10.1007/s10269-009-1851-5

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Luporsi, É., André, F., Bellocq, J. P., Caron, Y., Fumoleau, R. P., Gompel, A., Martin, P. M., Roché, H., Salmon, R., Sigal-Zafrani, B., & Spyratos, F. (2010). Rapport 2009 sur l'état des connaissances relatives aux biomarqueurs tissulaires uPA/PAI-1, Oncotype DX™ et MammaPrint® dans la prise en charge du cancer du sein. Oncologie, 12(2), 158-163. https://doi.org/10.1007/s10269-009-1851-5

@article{df69677051394f14ab6a1c20c90562da,

title = "Rapport 2009 sur l'{\'e}tat des connaissances relatives aux biomarqueurs tissulaires uPA/PAI-1, Oncotype DX{\texttrademark} et MammaPrint{\textregistered} dans la prise en charge du cancer du sein",

abstract = "This report evaluates the prognostic and the predictive values of the following tumor markers in breast cancer management: uPA/PAI-1, Oncotype DX{\texttrademark}, and MammaPrint{\textregistered}. The report is based on literature appraisal and judgment of a panel of experts. For the prognostic value, only uPA/PAI-1 reached the highest level of evidence, LOE I. Because meta-analysis and dedicated randomized clinical trials were lacking, Oncotype DX{\texttrademark} and MammaPrint{\textregistered} reached lower levels of evidence, LOE II and LOE III, respectively. For the predictive value, only uPA/PAI-1 and Oncotype DX{\texttrademark} reached the intermediate level of evidence, LOE II. This review also describes the analytical methods, identifies the main ongoing clinical trials, and proposes perspectives for further research. This work was elaborated by the French National Cancer Institute (INCa) and the Soci{\'e}t{\'e}fran{\c c}aise de s{\'e}nologie et de pathologie mammaire.",

keywords = "Breast cancer, MammaPrint{\textregistered}, Oncotype DX{\texttrademark}, Predictive value, Prognostic value, uPA/PAI-1",

author = "{\'E}lisabeth Luporsi and Fabrice Andr{\'e} and Bellocq, {Jean Pierre} and Yves Caron and Fumoleau, {Reims Pierre} and Anne Gompel and Martin, {Pierre Marie} and Henri Roch{\'e} and R{\'e}my Salmon and Brigitte Sigal-Zafrani and Fr{\'e}d{\'e}rique Spyratos",

year = "2010",

month = feb,

day = "1",

doi = "10.1007/s10269-009-1851-5",

language = "Fran{\c c}ais",

volume = "12",

pages = "158--163",

journal = "Oncologie",

issn = "1292-3818",

number = "2",

}

Luporsi, É, André, F, Bellocq, JP, Caron, Y, Fumoleau, RP, Gompel, A, Martin, PM, Roché, H, Salmon, R, Sigal-Zafrani, B & Spyratos, F 2010, 'Rapport 2009 sur l'état des connaissances relatives aux biomarqueurs tissulaires uPA/PAI-1, Oncotype DX™ et MammaPrint® dans la prise en charge du cancer du sein', Oncologie, VOL. 12, Numéro 2, p. 158-163. https://doi.org/10.1007/s10269-009-1851-5

Rapport 2009 sur l'état des connaissances relatives aux biomarqueurs tissulaires uPA/PAI-1, Oncotype DX™ et MammaPrint® dans la prise en charge du cancer du sein. / Luporsi, Élisabeth; André, Fabrice; Bellocq, Jean Pierre et al.
Dans: Oncologie, Vol 12, Numéro 2, 01.02.2010, p. 158-163.

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

TY - JOUR

T1 - Rapport 2009 sur l'état des connaissances relatives aux biomarqueurs tissulaires uPA/PAI-1, Oncotype DX™ et MammaPrint® dans la prise en charge du cancer du sein

AU - Luporsi, Élisabeth

AU - André, Fabrice

AU - Bellocq, Jean Pierre

AU - Caron, Yves

AU - Fumoleau, Reims Pierre

AU - Gompel, Anne

AU - Martin, Pierre Marie

AU - Roché, Henri

AU - Salmon, Rémy

AU - Sigal-Zafrani, Brigitte

AU - Spyratos, Frédérique

PY - 2010/2/1

Y1 - 2010/2/1

N2 - This report evaluates the prognostic and the predictive values of the following tumor markers in breast cancer management: uPA/PAI-1, Oncotype DX™, and MammaPrint®. The report is based on literature appraisal and judgment of a panel of experts. For the prognostic value, only uPA/PAI-1 reached the highest level of evidence, LOE I. Because meta-analysis and dedicated randomized clinical trials were lacking, Oncotype DX™ and MammaPrint® reached lower levels of evidence, LOE II and LOE III, respectively. For the predictive value, only uPA/PAI-1 and Oncotype DX™ reached the intermediate level of evidence, LOE II. This review also describes the analytical methods, identifies the main ongoing clinical trials, and proposes perspectives for further research. This work was elaborated by the French National Cancer Institute (INCa) and the Sociétéfrançaise de sénologie et de pathologie mammaire.

AB - This report evaluates the prognostic and the predictive values of the following tumor markers in breast cancer management: uPA/PAI-1, Oncotype DX™, and MammaPrint®. The report is based on literature appraisal and judgment of a panel of experts. For the prognostic value, only uPA/PAI-1 reached the highest level of evidence, LOE I. Because meta-analysis and dedicated randomized clinical trials were lacking, Oncotype DX™ and MammaPrint® reached lower levels of evidence, LOE II and LOE III, respectively. For the predictive value, only uPA/PAI-1 and Oncotype DX™ reached the intermediate level of evidence, LOE II. This review also describes the analytical methods, identifies the main ongoing clinical trials, and proposes perspectives for further research. This work was elaborated by the French National Cancer Institute (INCa) and the Sociétéfrançaise de sénologie et de pathologie mammaire.

KW - Breast cancer

KW - MammaPrint®

KW - Oncotype DX™

KW - Predictive value

KW - Prognostic value

KW - uPA/PAI-1

UR - http://www.scopus.com/inward/record.url?scp=77953564031&partnerID=8YFLogxK

U2 - 10.1007/s10269-009-1851-5

DO - 10.1007/s10269-009-1851-5

M3 - Article 'review'

AN - SCOPUS:77953564031

SN - 1292-3818

VL - 12

SP - 158

EP - 163

JO - Oncologie

JF - Oncologie

IS - 2

ER -